Canada Markets closed

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1000+0.0300 (+2.80%)
At close: 4:00PM EDT
1.0900 -0.01 (-0.91%)
After hours: 07:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.0700
Bid1.0800 x 1400
Ask1.1000 x 4000
Day's Range1.0500 - 1.1000
52 Week Range0.8500 - 2.8000
Avg. Volume1,823,168
Market Cap44.087M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.4040
Earnings DateNov. 10, 2021 - Nov. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
  • Newsfile

    Highlights and Insights into Soligenix

    Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized Vaccines New York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (NASDAQ: SNGX), spoke about the latest developments with their synthetic hypericin topical treatment HyBryte™ and the Company's ongoing research and development of thermostabilized vaccine candidates for filoviruses and

  • Newsfile

    Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic

    COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta Variants New York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and administering COVID-19 vaccines that need to be stored at sub-zero temperatures is hampering the pandemic recovery efforts of health professionals around the world. Soligenix, Inc (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, is developing a solution to that problem. The Company

  • Newsfile

    Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics

    Soligenix discusses its contribution to addressing future serious public health threats in a podcast New York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has already cost the United States an estimated $16 trillion in lost economic output, and has resulted in the loss of over 600,000 lives. At the end of last month, the country reached the dubious milestone of 39 million diagnosed cases of COVID, however, researchers ...